At Virion Therapeuticswe Believe A Future Free Of Cancer And Chronic Infectious Diseases Is Within Reachae Driven By Scienceour Mission Is To Revolutionize The Immunotherapy Treatment Landscapefocusing On The Development Of Noveladaptableand Accessible Cd8 Ae T Cell Based Technologies Ae Our Transformative Platform Is First In Its Classoffering A Unique Methodology That Combines Innovative And Established Approaches To Elicit A Superior Cd8 Ae T Cell Responsenovel Genetically Encoded Checkpoint Modifiers Are Delivered Alongside Optimized Target Specific Antigens Via An Immunogenic And Adaptable Viral Vector Platform That Promotes Potentprolongedand Broad Cd8 Ae T Cell Responses With Potential Applications Across A Range Of Cancers And Chronic Infectious Diseasesour Proprietary Technology Provides Us With A Robust Pipelineour Lead Productvron 0200Is Under Investigation As A Potential Functional Cure For The Treatment Of Chronic Hepatitis B Virushbvaea First In Human Clinical Study Is Planned To Initiate In Late 2022 Founded In 2018 To Advance Technology Licensed From The Wistar Institutewe Have Assembled A World Class Management Team And An Industry Leading Global Board Of Directorswith Proven Experience In The Biotechnology Sectoras Well As Extensive Preclinical And Clinical Expertise In Antiviralvaccineoncologyand Immuno Oncology Ae
